Big pharma, Partnering, Pharma

Roche and 4D Molecular partner for AAV vectors

Posted on 30 April 2015

Tags: , ,

4D Molecular Therapeutics announced a collaboration and license agreement with Roche to discover and develop optimized next-generation AAV vectors for indications with high unmet medical need.

4DMT will deploy its proprietary AAV vector discovery platform, Directed Vector Evolution, to identify and optimize novel gene delivery vectors for use in gene therapy products.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

 

Financial details were not disclosed.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2015

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply